A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. - Wikidata - awgldk - TriplyDB

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.

http://www.wikidata.org/entity/Q34946650

about

Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage Vaccine adjuvants as potential cancer immunotherapeutics Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity Therapeutic cancer vaccines: past, present, and future Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease Integrated analysis of incidence, progression, regression and disappearance probabilities Purification of a mycobacterial adhesin for fibronectin.A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.Toll-like receptor agonists in cancer therapy.An overview of cancer immunotherapy.Bladder cancer: a review of diagnosis and management.Activation of anti-tumor immune response and reduction of regulatory T cells with Mycobacterium indicus pranii (MIP) therapy in tumor bearing mice.Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.The origins of urothelial carcinoma.The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.Development of replication-competent adenovirus for bladder cancer by controlling adenovirus E1a and E4 gene expression with the survivin promoter Cancer immunotherapy in clinical practice -- the past, present, and future.Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines Update on intravesical agents for non-muscle-invasive bladder cancer Superficial bladder cancer T1G3: the choice of treatment.Photodynamic therapy for superficial bladder cancer.Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review.Use of bacille Calmette-Guérin in superficial bladder cancer.N1-guanyl-1,7-diaminoheptane sensitizes bladder cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2 activation.En bloc transurethral resection with 2-micron continuous-wave laser for primary non-muscle-invasive bladder cancer: a randomized controlled trial.Adjuvant intravesical therapy for superficial bladder cancer.Compliance with guidelines for patients with bladder cancer: variation in the delivery of care.Quality of care in patients with bladder cancer: a case report?Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells.Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro Current state of immunotherapy for bladder cancer.Antisense oligonucleotides in the treatment of bladder cancer.GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy.Bladder Cancer Immunotherapy: BCG and Beyond.Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation for Non-muscle Invasive Bladder Cancer.

P2860

Q24799512-BA713449-25E8-46C4-97AA-B1DC17482093 Q26739003-FEB8B715-0565-4346-84A8-DB80716A5CBE Q26752522-71C22A82-36A9-4CA9-94B2-B230B7CB7C6C Q26765115-C6A14FB3-E4B9-4BD2-9122-C4A50D77A863 Q26782131-09939833-85DF-4FD2-824F-47BD1A013C46 Q26863283-FEE18FBD-4C87-4936-9559-DEF15B1E10C6 Q27011829-4A750E28-3083-4EB1-AB7E-4B356903026E Q28076041-7E88EAD0-67D1-476B-B5F1-EC58AD6C5628 Q31112248-B6E0043D-49AF-4009-9B2A-A0E5A2689DD8 Q33346501-A110DE5B-3598-4F3C-A057-138BE50720CF Q33595808-7CFB9718-95B0-4260-AB7C-0DB6ECFDC34C Q33640357-55196EDD-F54E-4486-966B-D0945DCBD670 Q33918509-DCCB912E-6575-412F-BF04-9EC52E8A9EAA Q33940388-A34875B8-F97A-4BA1-A1A8-724F90484EDA Q33986470-57B0F94E-E169-4E6B-BC5B-29E33184690D Q34044931-B2A94061-70E3-4306-A55E-6F403B206DD2 Q34048705-F5EE829A-1E9F-496E-B795-944FAA610342 Q34121078-B3FDF654-0380-4A06-B202-D8857E0B1BB2 Q34147692-5698514F-6458-4664-B330-D9160BD38F8F Q34221639-D5937D00-71B9-4CD9-99FE-C1B6E53B98B1 Q34309399-3C104529-BE67-45DD-97D6-3B77BC900A47 Q34318570-50F0D4C4-A752-4826-BB56-A27184F3C348 Q34433649-611A632F-7206-40EE-AE25-AA60E9D585A0 Q34584575-19EF9EB4-200C-4E62-9FD1-A0C2CA62C253 Q34593849-9F3E5C5D-8FDF-4885-92F3-31126E17C371 Q34734143-A948ECB2-C7FC-43EC-A26C-1053D565FF2F Q34751946-3170905D-B646-4DE4-8492-00584E963574 Q34788204-894E7B9C-DB6F-450B-B45D-C926C2C5AB3E Q35051469-7AFAFE1F-C34B-4D83-AC1D-8C86CD397CAE Q35192401-F0594040-624E-4D7A-9E33-B4EC5BF9AC65 Q35466482-F8A4C755-0D9A-46B3-9062-C77E227CF2B3 Q35501135-BA869B44-5E00-4201-A6B8-3F39A492A935 Q35541862-4D9E983D-F568-4B16-8BC7-0464A5056595 Q35823499-68CFFED1-57BD-4B6E-9369-2BF1ACA13C08 Q35849100-C58F69BD-CAE9-45B5-B23F-953A07E5CC47 Q35987752-2114FCFC-891F-4E9F-B7D6-9BE3473BC57B Q36040819-4A063F4D-039A-4B26-97DB-32DB39BFB139 Q36044627-C328931C-C8B6-4C1E-8472-DD6D01034C75 Q36072179-29C38629-5E80-4640-BD07-C8D3A4458E48 Q36137539-9DB903E2-1DAE-45CA-8C5A-37170F0DD865

P2860

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.

http://www.wikidata.org/entity/Q34946650

description

1991 nî lūn-bûn

@nan

1991 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1991 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

1991年の論文

@ja

1991年論文

@yue

1991年論文

@zh-hant

1991年論文

@zh-hk

1991年論文

@zh-mo

1991年論文

@zh-tw

1991年论文

@wuu

name

A randomized trial of intraves ...... cell carcinoma of the bladder.

@ast

A randomized trial of intraves ...... cell carcinoma of the bladder.

@en

A randomized trial of intraves ...... cell carcinoma of the bladder.

@nl

type

label

A randomized trial of intraves ...... cell carcinoma of the bladder.

@ast

A randomized trial of intraves ...... cell carcinoma of the bladder.

@en

A randomized trial of intraves ...... cell carcinoma of the bladder.

@nl

prefLabel

A randomized trial of intraves ...... cell carcinoma of the bladder.

@ast

A randomized trial of intraves ...... cell carcinoma of the bladder.

@en

A randomized trial of intraves ...... cell carcinoma of the bladder.

@nl

P1433

Q34946650-DFE118AE-D239-48DD-8593-9FC0E713B246

P1476

Q34946650-43D8B512-0E1A-476F-8CE2-6D3466CB37B0

P2093

Q34946650-1D2C4556-8038-4ABA-B41C-535C551C3636

Q34946650-485DC841-ACD8-4879-9235-108D55B945E7

Q34946650-5D44273C-035B-4193-9F48-E660BAD3A91C

Q34946650-926FB565-21ED-4250-BC3F-2175D8612F01

Q34946650-9A1BD204-35C3-4205-B9ED-2D73FB6FF4EF

Q34946650-AD83892D-79AE-43C2-B4FB-343B2EBB4EB6

Q34946650-D106FC72-BFEA-4FEC-877A-A3EE28A705C9

Q34946650-ECA76736-1D64-4388-B28A-A6B87CB3AADD

Q34946650-F1F8D87A-4781-4F34-8B22-E26E028548D7

Q34946650-FB737F97-51BE-461D-9EE3-DF2B16F009AA

P304

Q34946650-3F1C652B-4FB9-4A5C-AA44-DF00D39A0C24

P31

Q34946650-28959081-01DC-48BB-BC06-71219403D894

P356

Q34946650-8EB53AA9-E32E-49A8-AF66-A4A7AAEA3718

P407

Q34946650-E35E97BC-4820-46B7-BAFA-B5EB118CAAF7

P433

Q34946650-4D27A073-DE08-4DDC-9B67-9E5194E9DB78

P478

Q34946650-68731137-7D64-4A43-BE74-9A772018D544

P577

Q34946650-339DA1FD-2B96-4697-9C62-4002BD97257C

P698

Q34946650-A773C863-12F8-4801-9B70-C321C3A3922B

P921

Q34946650-63F7BE57-0C2D-4053-B8AC-6069EA197E0A

P356

NEJM199110243251703

P1433

The New England Journal of Medicine

P1476

A randomized trial of intraves ...... cell carcinoma of the bladder.

@en

P2093

Blumenstein BA

http://www.w3.org/2001/XMLSchema#string

Crawford ED

http://www.w3.org/2001/XMLSchema#string

Grossman HB

http://www.w3.org/2001/XMLSchema#string

Lamm DL

http://www.w3.org/2001/XMLSchema#string

Montie JE

http://www.w3.org/2001/XMLSchema#string

Sarosdy MF

http://www.w3.org/2001/XMLSchema#string

Scardino P

http://www.w3.org/2001/XMLSchema#string

Smith JA Jr

http://www.w3.org/2001/XMLSchema#string

Stanisic TH

http://www.w3.org/2001/XMLSchema#string

Sullivan J

http://www.w3.org/2001/XMLSchema#string

P304

1205-1209

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJM199110243251703

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

325

http://www.w3.org/2001/XMLSchema#string

P577

1991-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

1922207

http://www.w3.org/2001/XMLSchema#string

P921